Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Ireland

European Innovation Council · Finished

AVeta Hormone-free solution for vaginal atrophy

Coordinator
Aveta Medical Limited, Ireland
Runs
1 April 2022 to 31 December 2024
Status
Finished
EU funding
€2.5m
Total cost
€3.8m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190178595

What the project is doing

In the project's own words, from its summary on CORDIS.

Vaginal Atrophy (VA) is a chronic and progressive condition. VA impacts on the quality of life, relationships, everyday activities and confidence of women sufferers. It is associated with thinning, drying and inflammation of the vaginal tissue. It is experienced by 80% of all women globally and is the most common symptom of the menopause. Over 70% of Breast Cancer Survivors will also suffer from VA due to side effects of chemotherapy and the cancer-blocker drugs they take further exacerbate symptoms of VA.

Current treatment options for VA, primarily pharmaceuticals are either ineffective or poorly tolerated. In the EU and US, 3.6m patients of VA reject existing treatments. AVeta- a medical device delivering the only hormone free, affordable and safe targeted therapy for all women suffering from VA. Solution is based on pathophysiology of wound healing and will be prescribed by a Clinician in an outpatient setting and women will self-administer the therapy monthly at home.

Topics

Who is involved

OrganisationCityCountryRole
Aveta Medical LimitedGalwayIrelandCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI